Garthedipine — Newly-Discovered Drug Essay Example
Calcium channel blockers are drugs utilized by hypertension patients, whereby they slow calcium movement into the heart cells as well as blood vessel walls; thus, enabling the heart to pump effectively. Consequently, the heart is relieved some work and it does not have to work very hard leading to lower blood pressure. The newly-discovered drug (Garthedipine) will face competition from other calcium channel blockers such as Lacidipine, Amlodipine, Felodipine, Nifedipine, Isradipine, Nicardipine, Lercanidipine as well as Nisoldipine. Garthedipine will be effective antihypertensive agent due to the peripheral vasodilation. Besides that, Garthedipine will effectively combine with renin-angiotensin system blocking drugs so as to generate overall antihypertensive effects that are at least additive. Basically, the process of drug development will be divided into three key steps: the discovery process, preclinical development step as well as the clinical trial. As mentioned by reference, drug candidate selection is attributed to the results of toxicology testing and preliminary pharmacology (Steinmetz & Spack, 2009). Without a doubt, the path to Garthedipine will not just be long, but very costly, plagued with disappointments and fraught with potholes. In this case, the drug development team will first identify a target that is considered suitable. The target will be a protein receptor, which is exactly related to the hypertension such as the G-protein—coupledreceptor. In this case, it is imperative to comprehend how hypertension takes place at the genetic, cellular and molecular levels. Upon identifying the target, the team will examine how the role played by the target in the disease process.
Subsequently, the target will be tested against various known as well as new compounds with the goal of identifying a number of ‘lead compounds’ that interact with the target and exhibit its ability to either slow or neutralize hypertension. Imperatively, the drug development stage will entail optimization and rigorous testing of the chosen compounds so as to ascertain the ‘candidate drug or lead structure’ that will be more effective. Furthermore, testing will be carried out in the cells to examine metabolism (pharmacokinetics as well as pharmacodynamics), effectiveness, toxicity, safety, and dosage. The process whereby candidate drug is comprehensively examined, improved, and prepared for human testing is known as the preclinical phase. In the last phase, the clinical phase, the safety as well as efficacy of Garthedipine will be investigated in patients. Basically, clinical trials signify the final premarket testing ground for Garthedipine. During such trials, Garthedipine will be administered to humans and tested for its effectiveness and safety in treating and preventing, hypertension. The clinical trials results will involve determine the approval or disapproval of Garthedipine. In spite of cautious planning, the majority of drug candidates normally fail because of undesirable side effects such as life threatening side effects, poor biodistribution, poor solubility, high costs of manufacturing, poor effectiveness during the clinical trials, and market competition. To overcome these challenges, the development team will set clear criteria as well as formulate a preclinical strategy that emphasize on key issues identification so as to get rid of problematic drug candidates early during the process of discovery.
Steinmetz, K.L. & Spack, E.G., 2009. The basics of preclinical drug development for neurodegenerative disease indications. [Online] Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697630/ [Accessed 8 February 2016].
More Important Things